Kai Zhao, was born on December 6 of 1930 in Suzhou City Jiangsu Province. He is a Medical Virologist and the member of Chinese Communist Party. Zhao graduated from the Department of Biology, Fudan University in 1954. He was the former Director General of the National Vaccine Serum (NVSI) and now is the Advisory of NVSI.

Zhao has been engaged into the research and development of viral vaccines for decades. Since the 1960s, he successively led the R&D of cell culture smallpox vaccine, rubella attenuated live vaccine and blood source hepatitis B vaccine at NVSI. In the late 80, he drove the collaboration between NVSI with the Shanghai Biochemical Institute of Chinese Academy of Sciences on the development of a recombinant vaccinia hepatitis B vaccine, and then he led NVSI team to transfer the technology of recombinant yeast Hepatitis B from MSD to NVSI, and subsequently made further improvement on the quality and capacity of the vaccine, to meet the needs of hepatitis B immunization to newborn. In 21st century, he deeply engaged into the mechanism research of antigen-antibody complex immunotherapy for HBV infection and the first innovative research of the national integrated prevention and control of the Pandemic Influenza H1N1. The above achievements were awarded three National Prizes for Progress of Science and Technology, three Ministry Prizes for Progress of Science and Technology and one Ministry Prize of Natural Science. In 1997, he was elected the Academician of Chinese Academy of Engineering.